March #178 : What You Should Know About HIV and Hepatitis - by Laura Whitehorn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Features

The Right to Give Life

The House That Love Built

From the Editor

Life and Death

Feedback

Letters- March 2012

The POZ Q+A

Speaking of Sex...

What You Need to Know

Gay Rights Go Global

Join POZ on the Road to Washington

Hershey's Bittersweet

HIV Isn't Bioterrorism

General Hospital Says Goodbye to HIV-Positive Character

We Hear You

Legalize It

What Matters to You

Helping to Find a Cure for AIDS

Treatment News

Bill Clinton Proposes Generic Pricing for HIV Meds in the U.S.

Rituxan Boosts Lymphoma Survival Rates

Microsoft Joins the Hunt for an HIV Vaccine

What You Should Know About HIV and Hepatitis

40% of Americans With HIV Are Older Than 50

Misuse of Neti Pots Can Be Deadly

GMHC Treatment Issues March 2012

Comfort Zone

Easing the Winter Woes

POZ Heroes

Best in Show

   
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

March 2012

What You Should Know About HIV and Hepatitis

by Laura Whitehorn

Two new protease inhibitors (PIs) for hep C are showing promise in people who also have HIV. Some 70 percent of people with both HIV and hepatitis C virus (HCV) had undetectable HCV viral loads after 24 weeks of treatment with either Incivek (telaprevir) or Victrelis (boceprevir) plus pegylated interferon and ribavirin. The study, looking at how people with HIV and hep C do when Incivek or Victrelis is added to the standard hep C regimen, is ongoing.

Looking forward to continued good reports on the drugs, experts have issued guidelines on the use of HCV PIs in people living with HIV. (Incivek and Victrelis can be prescribed off-label for people living with both viruses before the drugs get FDA approval for coinfection, but interaction with HIV regimens must be considered.)

Chronic hepatitis B virus (HBV) coinfection raises the risk of AIDS-related illness or death in people living with HIV—nearly double, in fact. So get tested for hep B, and if you don’t have it, get vaccinated.

If you do have hep B, be sure to include in your HIV regimen a med that’s active against both HIV and HBV—such as Epivir (lamivudine), Emtriva (emtricitabine), Viread (tenofovir) or Truvada (tenofovir/emtricitabine).

Click here to learn more.

Search: HCV, hepatitis C, coinfection, protease inhibitors, Incivek, telaprevir, Victrelis, boceprevir, pegylated interferon, ribavirin, HBV, hepatitis B virus


Scroll down to comment on this story.

email print



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    Hillcrester
    Ramona
    California


    Reginaldb06
    Dallas
    Texas


    max38man
    Chicago
    Illinois


    RayOctober
    Richmond
    Virginia
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Will decriminalizing injection drug use help end the global HIV epidemic?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.